Zobrazeno 31 - 40
of 84
pro vyhledávání: '"329"'
Autor:
Sally Rose Paredes, Myriam Rodríguez, Maria Elena Cabrera, Victoria Otero, Brady E Beltran, Fabiola Valvert Gamboa, Carlos S. Chiattone, Teodoro Chisesi, Raul Gabus, Gregorio Ignacio, Gabriel Borelli, Denisse Castro, Jorge J. Castillo, Camila Peña, Abel Berrios, Eduardo M. Sotomayor, Marialejandra Torres Viera
Publikováno v:
Blood. 132:2987-2987
Introduction: Diffuse large B-Cell Lymphoma (DLBCL) is the most frequent subtype of lymphoma in the world. The IPI score is a powerful risk-stratification tool in patients with DLBCL. The neutrophil-to-lymphocyte ratio (NLR) has shown to be prognosti
Autor:
Andrea Arruda, Steven M. Chan, Mark D. Minden, Hassan Sibai, Georgina S. Daher-Reyes, Aaron D. Schimmer, Jaime O. Claudio, Tracy Stockley, Vikas Gupta, Caroline J McNamara, Suzanne Kamel-Reid, Karen W.L. Yee, Andre C. Schuh, Dawn Maze, Reem Abdulrahman Alkharras, Manjula Maganti, Jose Mario Capo-Chichi
Publikováno v:
Blood. 132:2666-2666
Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous disease. Traditionally, cytogenetic analysis has been the backbone for prognostication and treatment decisions. Outcomes vary between age groups with older adults generally h
Autor:
Nicholas Finn, Nancy Zhu, Martha Lenis, Lisa Chodirker, Brian Leber, Mary-Margaret Keating, Michelle Geddes, Danielle N. Blunt, Kenneth Rockwood, Jill Fulcher, Robert Delage, Versha Banerji, Karen W.L. Yee, Rena Buckstein, Eve St-Hilaire, Mitchell Sabloff, Liying Zhang, Richard A. Wells, Alexandre Mamedov, Mohamed Elemary, April Shamy, Heather A. Leitch
Publikováno v:
Blood. 132:4850-4850
Background: Health-Related Quality of life (HRQoL) is diminished in patients with myelodysplastic syndrome (MDS). We have previously shown that HRQoL remains stable over time and low hemoglobin, transfusion dependence (TD) and age > 65 years impact Q
Autor:
Veronika Buxhofer-Ausch, Marco Ruggeri, Tiziano Barbui, Ayalew Tefferi, Juergen Thiele, Valerio De Stefano, Maria Luigia Randi, Guido Finazzi, Elisa Rumi, Alessandro Rambaldi, Heinz Gisslinger, Silvia Betti, Francesco Passamonti, Irene Bertozzi, Francesco Rodeghiero, Alessandro M. Vannucchi, Alessandra Carobbio
Publikováno v:
Blood. 120:5128-5133
Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform for prospective studies exploring preventive measures. Current risk stratification for thrombosis in ET is 2-tiered and considers low- and high-risk categories
Autor:
Yasuo Morishima, Mina Nishimori, Shunichi Fukuhara, Yuichi Akiyama, Keiko Hoshi, Yoshitsugu Yamada, Yoshihisa Kodera, Yasutaka Hoshi, Masahiro Tsuchida
Publikováno v:
Blood. 99:1995-2001
To promote bone marrow donation, both the safety and well-being of healthy unrelated volunteer donors must be protected. This prospective cohort study evaluated donors' health-related quality of life (HRQOL) and identified factors associated with it.
Autor:
Erin Morris, John S. Holcenberg, F. Leonard Johnson, Stanton Goldman, Raymond J. Hutchinson, Jerry Z. Finklestein, Susan G. Kreissman, Elizabeth Harvey, Conrad Tou, Mitchell S. Cairo
Publikováno v:
Blood. 97:2998-3003
Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uric acid to a 5 times increased urine soluble product, allantoin
Autor:
Russell Saal, Paula Marlton, Luen Bik To, Thomas J. Gonda, Sarah C Bray, Kyaw Ze Ya Maung, Mahmoud A. Bassal, Devinder Gill, James X Gray, Adam D. Ewing, Ian D. Lewis, Evgeny A. Glazov, Debora A. Casolari, Emma L. Duncan, Paul Leo, Richard J D'Andrea, Anna L. Brown
Publikováno v:
Blood. 128:41-41
While there have been extensive studies to define the roles of recurrent somatic mutations in AML, the contribution of germline variants to AML initiation and progression is less well established. DNA repair disorders often predispose patients to dev
Autor:
Kathryn Humphrey, Alexandra Bazeos, Francine Swann, Nelson Kinnersley, Othman Al-Sawaf, Noelle Crompton, Craig Gower, Günter Fingerle-Rowson, Peter Trask, Mark Dixon, Valentin Goede
Publikováno v:
Blood. 128:4352-4352
BACKGROUND The evaluation of response to therapy in CLL is widely assessed according to the iwCLL guidelines which define progressive disease (PD) as advancing lymphocytosis, lymphadenopathy, organomegaly, cytopenias or histological transformation (H
Autor:
Wilson I. Gonsalves, Ronald S. Go, Nidhi Tandon, John A. Lust, Amie Fonder, Surbhi Sidana, Angela Dispenzieri, Nelson Leung, Steven R. Zeldenrust, Suzanne R. Hayman, Miriam Hobbs, Shaji Kumar, Martha Q. Lacy, Robert A. Kyle, Stephen J. Russell, Yi L. Hwa, Francis K. Buadi, S. Vincent Rajkumar, David Dingli, Morie A. Gertz, Prashant Kapoor
Publikováno v:
Blood. 128:4627-4627
Introduction High dose chemotherapy and autologous stem cell transplantation (ASCT) is an effective therapy for eligible patients with newly diagnosed systemic AL amyloidosis. Dose attenuated melphalan is used in patients with older age, renal dysfun
Autor:
Leslie A. Andritsos, Natarajan Muthusamy, Qiuhong Zhao, John C. Byrd, Jennifer A. Woyach, Heather Breidenbach, Jeffrey Jones, Amber Gordon, Meixiao Long, Nyla A. Heerema, Caitlin Coombes, Farrukh T. Awan, Amy S. Ruppert
Publikováno v:
Blood. 128:4372-4372
Chronic Lymphocytic Leukemia (CLL) has a varied clinical course; some patients experience a long survival and others succumb to disease in a short time. Clinical factors correlated with either time to first treatment (TFT) and/or overall survival inc